🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This phase II/III trial studies how well daunorubicin and cytarabine with o...
Status
Active Not Recruiting
Location
University of Arkansas for Medical Sciences
Start Date
2019-03-28
Trial ID
NCT03701308
The purpose of the study is to measure how the radiolabelled test medicine ...
Status
Completed
Location
Quotient Sciences Limited
Start Date
2018-08-14
Trial ID
NCT03606447
Treatments Being Tested
This bridging study will evaluate the efficacy of uproleselan, a specific E...
Status
Terminated
Location
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Start Date
2021-11-17
Trial ID
NCT05054543
Treatments Being Tested
The purpose of this study is to evaluate safety, tolerability and pharmacok...
Status
Completed
Location
Celerion
Start Date
2014-06
Trial ID
NCT02168595
The purpose of this study is to find out whether the drug uproleselan can h...
Status
Terminated
Location
The University of Michigan
Start Date
2021-11-12
Trial ID
NCT05057221
Treatments Being Tested
This research study is studying a new drug, uproleselan, to see if it is sa...
Status
Terminated
Location
University of Alabama Birmingham
Start Date
2022-10-06
Trial ID
NCT05569512
Treatments Being Tested
This study will evaluate GMI-1271, a specific E-selectin antagonist, in mul...
Status
Completed
Location
Vejle Hospital
Start Date
2016-06
Trial ID
NCT02811822
Treatments Being Tested
The investigators hypothesize that prophylactic E-selectin inhibition via a...
Status
Completed
Location
Washington University School of Medicine
Start Date
2021-05-05
Trial ID
NCT04682405
Treatments Being Tested
Phase 1, open-label, parallel, active-controlled, multiple IV dose, proof o...
Status
Completed
Location
Celerion
Start Date
2015-11
Trial ID
NCT02703051
Treatments Being Tested
This study will evaluate the safety and tolerability of uproleselan(GMI-127...
Status
Completed
Location
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Start Date
2021-02-24
Trial ID
NCT04839341
Treatments Being Tested